FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery
Combining two drugs offered no pain relief advantage over one drug alone
This randomized, triple-blind trial in 100 patients undergoing upper limb surgery found that adding i.v.
A trial of 100 patients found that adding dexmedetomidine to dexamethasone did not extend pain relief or reduce opioid use after upper limb …
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
High Inflammation Might Reduce Placebo Effect in Cancer
This exploratory analysis of an RCT in 45 cancer patients with dyspnea found a negative association between baseline cytokine levels and sym…
Scientists found that high inflammation levels may stop the placebo effect from working well.
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot
Early Meds Could Cut Hospital Stays for Wheezing Kids
This Phase 2 pilot trial in the Pediatric Emergency Care Applied Research Network assessed an EMS treatment bundle and checklist for childre…
Kids with severe asthma might avoid hospital stays if they get breathing meds right after the 911 call.
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer
Chemotherapy Steroids May Not Shut Down Your Body’s Stress System
This prospective pilot study included 47 women with breast cancer receiving paclitaxel and dexamethasone.
This small study suggests that the body’s natural ability to make stress hormones might stay intact during certain chemotherapy regimens, ea…
High-volume PENG block with dexamethasone showed no analgesic advantage over conventional volume in primary total hip arthroplasty
More Numbing Fluid Does Not Mean Less Pain
This randomized, controlled trial enrolled 40 patients undergoing primary total hip arthroplasty under spinal anesthesia.
Giving doctors more numbing medicine around the hip nerve does not help patients feel less pain after surgery.
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death
Rare Blood Cancer Causes Fast Kidney Failure
This case report and literature review describes a 75-year-old female with Waldenström macroglobulinemia and AL lambda-type amyloid nephropa…
When a rare blood cancer attacks the kidneys, standard treatments often fail to stop the fast progression to organ failure.
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.